

Rating Action: Octapharma Nordic AB

Moody's assigns Baa2 to Octapharma Nordic AB; stable outlook

Paris, November 30, 2007 -- Moody's Investors Services has today assigned a Baa2 senior unsecured long-term issuer rating to Octapharma Nordic AB ("Octapharma"). The rating outlook is stable. This is the first time Octapharma has been rated by Moody's.

"Octapharma's Baa2 rating reflects a number of operating and financial strengths," says Mr Jean-Michel Carayon, Senior Vice President at Moody's and lead analyst for Octapharma. These strengths comprise: (1) the positive demand trends in the plasma market, as reflected in the company's strong growth in sales in the last years; (2) the leading position of plasma-derived products in the European market; (3) the high barriers to entry of the plasma market in terms of manufacturing know-how, sourcing and regulatory requirements for manufacturing capacity; (4) the company's comprehensive product range in the market for plasma-derived pharmaceutical products supported by a solid research and development track record; (6) Moody's expectation that Octapharma's operating performance will have stable characteristics over the intermediate term with stable prices and solid growth; (7) the currently very strong financial structure with significant cash positions; and (8) the group's strong track record in safety and the expectation that the risk of litigation is much lower than in the pharmaceutical industry.

However, Moody's points out that the rating is also constrained by a number of factors, namely (1) the limited business diversification; (2) the risk relative to maintaining satisfactory sourcing over time, while internal sourcing remains limited although it is being increased; (3) the comparatively weaker position in some geographies such as the US market and the relative size compared to the two market leaders. Moreover, (4) Moody's also believes that a degree of potential downside can affect the company with the substitution of plasma-derived products by recombinant products. However, this should be mitigated by the limited applications of recombinant in various product areas and the development of recombinant products by Octapharma. In addition, (5) Moody's expects that the plasma market may face a less favourable balance over the long term than currently and that excess capacity may possibly drive lower prices and margins.

Overall, Moody's considers the plasma industry to be characterised by higher business risk than the average for the medical product sector, largely due to sourcing and pricing risk. In line with its medical products rating methodology, Moody's expects Octapharma rating to remain positioned around two or three notches below the calculated rating grid of Moody's rating methodology, currently A3 at year-end 2006 (please refer to Moody's Credit Opinion on Octapharma for further details). "However, this gap could narrow in the event that Octapharma uses its financial flexibility for acquisitions," indicates Mr Carayon. Moody's also expects that debt-financed acquisitions should not lead to a deterioration in credit metrics beyond a level of 2x Debt / EBITDA and that free cash flow will be used for debt reduction in case of debt-financed acquisitions. The currently strong financial profile leaves material leeway for debt-financed acquisitions.

The rating outlook is stable, in recognition of the reasonably predictable cash-flow generation over the next few years, the strong balance sheet and the conservative financial policy of the management.

The parent company Octapharma Nordic AB, based in Stockholm, Sweden, is a privately-owned European leading company producing plasma-derived products with Swiss-based headquarter operations. Its 2006 revenues amounted to EUR547 million.

Paris
Jean-Michel Carayon
Senior Vice President
Corporate Finance Group
Moody's France S.A.
JOURNALISTS: 44 20 7772 5456
SUBSCRIBERS: 44 20 7772 5454

Paris
Myriam Durand
Managing Director
Corporate Finance Group
Moody's France S.A.
JOURNALISTS: 44 20 7772 5456
SUBSCRIBERS: 44 20 7772 5454

© Copyright 2007, Moody's Investors Service, Inc. and/or its licensors including Moody's Assurance Company, Inc. (together, "MOODY'S"). All rights reserved.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY COPYRIGHT LAW AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY'S PRIOR WRITTEN CONSENT. All information contained herein is obtained by MOODY'S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, such information is provided "as is" without warranty of any kind and MOODY'S, in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness, completeness, merchantability or fitness for any particular purpose of any such information. Under no circumstances shall MOODY'S have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance or contingency within or outside the control of MOODY'S or any of its directors, officers, employees or agents in connection with the procurement, collection, compilation, analysis, interpretation, communication, publication or delivery of any such information, or (b) any direct, indirect, special, consequential, compensatory or incidental damages whatsoever (including without limitation, lost profits), even if MOODY'S is advised in advance of the possibility of such damages, resulting from the use of or inability to use, any such information. The credit ratings and financial reporting analysis observations, if any, constituting part of the information contained herein are, and must be construed solely as, statements of opinion and not statements of fact or recommendations to purchase, sell or hold any securities. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY SUCH RATING OR OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY'S IN ANY FORM OR MANNER WHATSOEVER. Each rating or other opinion must be weighed solely as one factor in any investment decision made by or on behalf of any user of the information contained herein, and each such user must accordingly make its own study and evaluation of each security and of each issuer and guarantor of, and each provider of credit support for, each security that it may consider purchasing, holding or selling.

MOODY'S hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MOODY'S have, prior to assignment of any rating, agreed to pay to MOODY'S for appraisal and rating services rendered by it fees ranging from \$1,500 to approximately \$2,400,000. Moody's Corporation (MCO) and its wholly-owned credit rating agency subsidiary, Moody's Investors Service (MIS), also maintain policies and procedures to address the independence of MIS's ratings and rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold ratings from MIS and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually on Moody's website at www.moody's.com under the heading "Shareholder Relations - Corporate Governance - Director and Shareholder Affiliation Policy."